ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · IEX Real-Time Price · USD
7.06
-0.01 (-0.14%)
Jul 22, 2024, 11:34 AM EDT - Market open
ClearPoint Neuro Employees
ClearPoint Neuro had 107 employees as of December 31, 2023. The number of employees decreased by 1 or -0.93% compared to the previous year.
Employees
107
Change (1Y)
-1
Growth (1Y)
-0.93%
Revenue / Employee
$244,495
Profits / Employee
-$192,766
Market Cap
194.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
EDAP TMS | 307 |
Personalis | 225 |
Generation Bio Co. | 174 |
G1 Therapeutics | 100 |
Lineage Cell Therapeutics | 75 |
Trevi Therapeutics | 25 |
Renovaro Biosciences | 12 |
CLPT News
- 4 days ago - ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024 - GlobeNewsWire
- 4 weeks ago - ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial - GlobeNewsWire
- 4 weeks ago - Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons - PRNewsWire
- 7 weeks ago - ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System - GlobeNewsWire
- 2 months ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT) - PRNewsWire
- 3 months ago - ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations - GlobeNewsWire
- 4 months ago - ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency - GlobeNewsWire
- 4 months ago - ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results - GlobeNewsWire